Pais Raluca, Ratziu Vlad
Service d'hépatologie, groupe hospitalier de La Pitié-Salpêtrière, AP-HP, université Pierre-et-Marie-Curie, 75013 Paris, France.
Rev Prat. 2012 Dec;62(10):1416-8, 1420-1.
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of diseases that ranges from simple steatosis to steatohepatitis (NASH), two entities with strikingly different outcomes. NAFLD is becoming one of the leading causes of chronic liver disease worldwide, but the real prevalence of the disease is still underestimated. NAFLD is strongly linked to insulin resistance and should be suspected in all patients with overweight, obesity, diabetes or other features of metabolic syndrome seeking medical care inside or outside Hepatology clinics. NASH is a slowly progressive fibrotic disease. Patients with NASH may develop cirrhosis, endstage liver disease and hepatocellular carcinoma. The overall and liver-related mortality are increased in patients with NASH compared to general population.
非酒精性脂肪性肝病（NAFLD）涵盖了一系列疾病，从单纯性脂肪变性到脂肪性肝炎（NASH），这两种病症的结局截然不同。NAFLD正成为全球慢性肝病的主要病因之一，但该疾病的实际患病率仍被低估。NAFLD与胰岛素抵抗密切相关，对于所有在肝病门诊内外寻求医疗服务、具有超重、肥胖、糖尿病或其他代谢综合征特征的患者，均应怀疑患有NAFLD。NASH是一种缓慢进展的纤维化疾病。NASH患者可能会发展为肝硬化、终末期肝病和肝细胞癌。与普通人群相比，NASH患者的全因死亡率和肝脏相关死亡率均有所增加。
